Psilera Appoints Neuroscience Veteran Allyson Gage, PhD, as Vice President, Clinical Development to Lead Upcoming Phase 1 Clinical Trial

Key appointment strengthens operational leadership as Psilera prepares its lead neuroplastogen, PSIL-006, for clinical-stage evaluation.

TAMPA, Fla., Aug. 27, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the appointment of Allyson Gage, PhD, as Vice President, Clinical Development. In this role, Dr. Gage will oversee the clinical development strategy and operational execution of the upcoming Phase 1 first-in-human clinical trials of Psilera's lead asset, PSIL-006.

Dr. Gage brings over 25 years of experience to Psilera, with a track record of advancing numerous compounds through FDA IND approval. Her expertise in biomarker identification and evaluation in CNS indications, small molecules, biologics, and cell therapies ideally positions her to lead Psilera's Phase 1 trial as VP, Clinical Development.

"Psilera is engineering tomorrow's therapies by leveraging the potential therapeutic power of neuroplastogens," states Dr. Gage. "I'm honored to join this team and to help guide PSIL-006 through the clinical milestones that will bring these treatments to the patients who need them."

The PSIL-006 Phase 1a clinical trial will evaluate safety, tolerability, and key biomarkers in human subjects, supporting its development for neuropsychiatric conditions such as depression, addiction, PTSD, and neurodegeneration. The trial follows significant corporate momentum for Psilera, including the close of an $8.8M oversubscribed seed funding round, key strategic partnerships, and institutional backing from the NIH through grant funding for IND-enabling studies.

"I am thrilled to partner with Dr. Gage once again as we advance the neuroplastogen pipeline at Psilera," expressed Magali Haas, MD-PhD, CMO of Psilera. "Allyson brings an exceptional combination of CNS drug development expertise and leadership with her impressive track record navigating the complex path from first-in-human studies through pivotal trials and ultimately regulatory approval."

About PSIL-006
PSIL-006 is a first-in-class neuroplastogen designed to harness the rapid therapeutic benefits of traditional psychedelics while reducing limiting factors such as clinic visits and hallucinations. Through Psilera's proprietary computational discovery platform, Psilera Third Eye ™, PSIL-006 has been engineered as a selective agonist at key serotonin receptors (5-HT2A, 5-HT2C, and 5-HT6) with a unique profile, enabling scalable, take-home dosing.

Learn more by visiting www.psilera.com.

Contact Information:

Investors: Monique Kosse, Gilmartin Group
[email protected]

Media: Katie DeMarsh, Director of Marketing
[email protected]

SOURCE Psilera, Inc.